Inhibikase Therapeutics (IKT) EPS (Basic) (2020 - 2024)
Historic EPS (Basic) for Inhibikase Therapeutics (IKT) over the last 5 years, with Q4 2024 value amounting to -$0.55.
- Inhibikase Therapeutics' EPS (Basic) rose 2536.09% to -$0.55 in Q4 2024 from the same period last year, while for Sep 2025 it was -$0.14, marking a year-over-year increase of 9364.39%. This contributed to the annual value of -$1.21 for FY2024, which is 6382.23% up from last year.
- Latest data reveals that Inhibikase Therapeutics reported EPS (Basic) of -$0.55 as of Q4 2024, which was up 2536.09% from -$0.66 recorded in Q3 2024.
- In the past 5 years, Inhibikase Therapeutics' EPS (Basic) registered a high of -$0.05 during Q2 2020, and its lowest value of -$1.11 during Q2 2023.
- For the 5-year period, Inhibikase Therapeutics' EPS (Basic) averaged around -$0.54, with its median value being -$0.6 (2024).
- Its EPS (Basic) has fluctuated over the past 5 years, first crashed by 48888.89% in 2022, then surged by 3962.01% in 2024.
- Over the past 5 years, Inhibikase Therapeutics' EPS (Basic) (Quarter) stood at -$0.15 in 2020, then plummeted by 88.23% to -$0.28 in 2021, then tumbled by 270.75% to -$1.03 in 2022, then increased by 28.84% to -$0.73 in 2023, then grew by 25.36% to -$0.55 in 2024.
- Its EPS (Basic) stands at -$0.55 for Q4 2024, versus -$0.66 for Q3 2024 and -$0.67 for Q2 2024.